Patient
SITE012-0012
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE012 (BRA) (Dr. Kowalski)
consented 2025-09-03
Adverse events
8
Serious AEs
1
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 8
Grade 3 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-03-08 (study day 359); relationship: not assessed
Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-02-13 (study day 336); relationship: not assessed; serious criteria: hospitalization
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-01-20 (study day 312); relationship: not assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-12-09 (study day 270); relationship: not assessed
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-11-07 (study day 238); relationship: not assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-10-20 (study day 220); relationship: NOT RELATED
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-09-19 (study day 189); relationship: not assessed
Grade 2 Alopecia — outcome: UNKNOWN; onset 2022-04-10 (study day 27); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.